Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,796.00
(
0.00%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
110.57
(
3.74%
)
Bitcoin
70,220.17
(
-1.43%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 88680

Friday, 02/18/2011 1:19:10 PM

Friday, February 18, 2011 1:19:10 PM

Post# of 257257
CHMP approves NVS’ Rasilamlo (Rasilez+Amlodipine) for hypertension:

http://www.reuters.com/article/2011/02/18/norvartis-idUSLDE71H1ER20110218

In the US, this product was approved in Aug 2010 (#msg-53782319) and is called Tekamlo (Tekturna+Amlodipine). A 3-in-1 variation with HCTZ added was approved in Dec 2010 (#msg-58062858) and is called Amturnide (Amlodipine+Tekturna+Hydrochlorothiazide).

Standalone sales of Tekturna/Rasilez have been disappointing; maybe these combination products will be material contributors.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now